Okamoto Yukiko, Takai Shinji, Miyazaki Mizuo
Department of Pharmacology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki City, Osaka 589-8686, Japan.
Eur J Pharmacol. 2004 Jan 26;484(2-3):357-9. doi: 10.1016/j.ejphar.2003.11.009.
To clarify the role of chymase in adhesion formation, we investigated whether a chymase inhibitor could prevent adhesion formation after surgery in hamsters. Hamsters received a lesion produced by uterus scraping. A specific chymase inhibitor, 2-[4-(5-fluoro-3-methylbenzo[b]thiophen-2-yl)sulfonamido-3-methanesulfonylphenyl]oxazole-4-carboxylicacid (TY-51184), or placebo was injected into the abdomen before closing and scores for adhesion formation were assessed at 1, 4, and 12 weeks. A single peritoneal administration of TY-51184 significantly decreased the adhesion scores even at 12 weeks (placebo, 2.80+/-0.20; chymase inhibitor, 1.60+/-0.31). Thus, chymase inhibitors may be a novel strategy to prevent adhesion formation.